(Q38217651)

31 August 2017

title

PI3K/AKT signaling pathway and cancer: an updated review (English)

1 reference

31 August 2017

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24897931%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

Miriam Martini

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24897931%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

Maria Chiara De Santis

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24897931%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

Federico Gulluni

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24897931%20AND%20SRC:MED&resulttype=core&format=json

Maria Laura Braccini Fagundes

6 June 2020

3

object named as

Laura Braccini

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24897931%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

language of work or name

English

0 references

publication date

5 June 2014

1 reference

31 August 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24897931%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

volume

46

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24897931%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24897931%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

page(s)

372-383

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24897931%20AND%20SRC:MED&resulttype=core&format=json

Common elements in growth factor stimulation and oncogenic transformation: 85 kd phosphoprotein and phosphatidylinositol kinase activity

6 June 2020

cites work

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

Association of phosphatidylinositol kinase activity with polyoma middle-T competent for transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

The emerging mechanisms of isoform-specific PI3K signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

Class IA phosphoinositide 3-kinases are obligate p85-p110 heterodimers

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

Class I PI3K in oncogenic cellular transformation.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

The nuts and bolts of AGC protein kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

Signalling through Class I PI3Ks in mammalian cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

An essential role for Rac in Ras transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

P-Rex1, a PtdIns(3,4,5)P3- and Gbetagamma-regulated guanine-nucleotide exchange factor for Rac

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

Role of substrates and products of PI 3-kinase in regulating activation of Rac-related guanosine triphosphatases by Vav

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

Interaction of Btk and Akt in B cell signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

A comparative analysis of the phosphoinositide binding specificity of pleckstrin homology domains

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

Phosphoinositides in cell regulation and membrane dynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

Mutational spectra of PTEN/MMAC1 gene: a tumor suppressor with lipid phosphatase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

MicroRNA-21 (miR-21) represses tumor suppressor PTEN and promotes growth and invasion in non-small cell lung cancer (NSCLC).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

PTEN function: how normal cells control it and tumour cells lose it

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

The 145-kDa protein induced to associate with Shc by multiple cytokines is an inositol tetraphosphate and phosphatidylinositol 3,4,5-triphosphate 5-phosphatase

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

Embryonic and hematopoietic stem cells express a novel SH2-containing inositol 5'-phosphatase isoform that partners with the Grb2 adapter protein

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

SHIP is a negative regulator of growth factor receptor-mediated PKB/Akt activation and myeloid cell survival

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

SHIP regulates the reciprocal development of T regulatory and Th17 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

Electrostatic control of the membrane targeting of C2 domains

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

IGF-1 mediates PTEN suppression and enhances cell invasion and proliferation via activation of the IGF-1/PI3K/Akt signaling pathway in pancreatic cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

Regulation and cellular functions of class II phosphoinositide 3-kinases.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

The Role of Phosphoinositide 3-Kinase C2α in Insulin Signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

Spatiotemporal control of endocytosis by phosphatidylinositol-3,4-bisphosphate

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

Endothelial PI3K-C2α, a class II PI3K, has an essential role in angiogenesis and vascular barrier function.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

Class II phosphoinositide 3-kinase defines a novel signaling pathway in cell migration.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

The activation of nuclear phosphoinositide 3-kinase C2beta in all-trans-retinoic acid-differentiated HL-60 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

The class II phosphoinositide 3-kinase C2beta is not essential for epidermal differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

Regulation of neuron survival through an intersectin-phosphoinositide 3'-kinase C2beta-AKT pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

A new dimension to Ras function: a novel role for nucleotide-free Ras in Class II phosphatidylinositol 3-kinase beta (PI3KC2β) regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

The regulation and function of Class III PI3Ks: novel roles for Vps34.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

Role for phosphatidylinositol 3-kinase in the sorting and transport of newly synthesized lysosomal enzymes in mammalian cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

Phosphatidylinositol 3-kinase encoded by yeast VPS34 gene essential for protein sorting

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

Amino acids mediate mTOR/raptor signaling through activation of class 3 phosphatidylinositol 3OH-kinase.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

hVps34 is a nutrient-regulated lipid kinase required for activation of p70 S6 kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

PI3K pathway alterations in cancer: variations on a theme

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

Phosphoinositide signalling in cancer: beyond PI3K and PTEN.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

The genomic landscapes of human breast and colorectal cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

Mechanism of constitutive phosphoinositide 3-kinase activation by oncogenic mutants of the p85 regulatory subunit

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

An integrated genomic analysis of human glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

PIK3R1 (p85α) is somatically mutated at high frequency in primary endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

Regulation of Class IA PI 3-kinases: C2 domain-iSH2 domain contacts inhibit p85/p110alpha and are disrupted in oncogenic p85 mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

High frequency of mutations of the PIK3CA gene in human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

Frequent mutation of the PIK3CA gene in ovarian and breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

PIK3CA cancer mutations display gender and tissue specificity patterns.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

The analysis of PIK3CA mutations in gastric carcinoma and metanalysis of literature suggest that exon-selectivity is a signature of cancer type.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

Prognostic Role of PIK3CA Mutation in Colorectal Cancer: Cohort Study and Literature Review

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

PIK3CA is implicated as an oncogene in ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

Phosphoinositide 3-kinase p110beta activity: key role in metabolism and mammary gland cancer but not development

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

A specific function for phosphatidylinositol 3-kinase alpha (p85alpha-p110alpha) in cell survival and for phosphatidylinositol 3-kinase beta (p85alpha-p110beta) in de novo DNA synthesis of human colon carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

Characterization of a tumor-associated activating mutation of the p110β PI 3-kinase.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

Oncogenic transformation induced by the p110beta, -gamma, and -delta isoforms of class I phosphoinositide 3-kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

BCR-ABL regulates phosphatidylinositol 3-kinase-p110gamma transcription and activation and is required for proliferation and drug resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

Identification of upregulated phosphoinositide 3-kinase γ as a target to suppress breast cancer cell migration and invasion

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

Key role of phosphoinositide 3-kinase class IB in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

Essential role for the p110 isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

Genetic heterogeneity of diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

Phosphoinositide 3-kinase δ gene mutation predisposes to respiratory infection and airway damage

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

Diverse somatic mutation patterns and pathway alterations in human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

Phosphatidylinositol 3-kinase (PI3K) pathway activation in bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

The phosphatidylinositol 3-Kinase AKT pathway in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

PI3Kinase signaling in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

PTEN level in tumor suppression: how much is too little?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

AKT/PKB signaling: navigating downstream

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

Cell survival and metastasis regulation by Akt signaling in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

AKT1 amplification regulates cisplatin resistance in human lung cancer cells through the mammalian target of rapamycin/p70S6K1 pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

A transforming mutation in the pleckstrin homology domain of AKT1 in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

AKT1(E17K) in human solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

Colorectal cancer: mutations in a signalling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

Deregulated Akt3 activity promotes development of malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

Inositol polyphosphate 4-phosphatase II regulates PI3K/Akt signaling and is lost in human basal-like breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

PTEN loss in the continuum of common cancers, rare syndromes and mouse models.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

Second-line therapy for refractory renal-cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

Clinical trial experience with temsirolimus in patients with advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

Development of everolimus, a novel oral mTOR inhibitor, across a spectrum of diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

The genetic basis of kidney cancer: a metabolic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

PIK3CA, BRAF, and PTEN status and benefit from cetuximab in the treatment of advanced colorectal cancer--results from NCIC CTG/AGITG CO.17.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

PIK3CA mutation is associated with poor survival among patients with metastatic colorectal cancer following anti-EGFR monoclonal antibody therapy: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

A phase I trial of liposomal doxorubicin, bevacizumab, and temsirolimus in patients with advanced gynecologic and breast malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

Requirement for interaction of PI3-kinase p110α with RAS in lung tumor maintenance

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

Crystal structure and functional analysis of Ras binding to its effector phosphoinositide 3-kinase gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

RAS and RHO families of GTPases directly regulate distinct phosphoinositide 3-kinase isoforms

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

Integrative genomic and proteomic analyses identify targets for Lkb1-deficient metastatic lung tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

Loss of LKB1 and PTEN tumor suppressor genes in the ovarian surface epithelium induces papillary serous ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

LKB1 is a central regulator of tumor initiation and pro-growth metabolism in ErbB2-mediated breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

KRASness and PIK3CAness in patients with advanced colorectal cancer: outcome after treatment with early-phase trials with targeted pathway inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

Molecular profiling of patients with colorectal cancer and matched targeted therapy in phase I clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

Intermittent administration of MEK inhibitor GDC-0973 plus PI3K inhibitor GDC-0941 triggers robust apoptosis and tumor growth inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

Utilizing targeted cancer therapeutic agents in combination: novel approaches and urgent requirements

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

Tumor genetic testing for patient selection in phase I clinical trials: the case of PI3K inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

Systematic identification of genomic markers of drug sensitivity in cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

Discovery of 2-{3-[2-(1-isopropyl-3-methyl-1H-1,2-4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl]-1H-pyrazol-1-yl}-2-methylpropanamide (GDC-0032): a β-sparing phosphoinositide 3-kinase inhibitor with high unbound exposure and ro

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

PI3-kinase inhibitors in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

Idelalisib and rituximab in relapsed chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

Characterization of the mechanism of action of the pan class I PI3K inhibitor NVP-BKM120 across a broad range of concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245408 (XL147), an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.912836

10.3109/07853890.2014.912836

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24897931%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

1 reference